HomeGALCANEZUMAB

  • FDA approves Galcanezumab (Emgality) for Preventive Migraine Treatment

    • October 8, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Galcanezumab reduces migraine days in patients failing on Botox

    • July 1, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Lilly to present Galcanezumab and Lasmiditan Ph 3 data at AHS 2018

    • June 27, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Lilly’s Galcanezumab Meets Primary Endpoint in Ph 3 Study for Episodic Cluster Headache

    • May 16, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Galcanezumab reduces Migraine days for patients failing on other therapies, highlights new subgroup analysis

    • April 26, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Migraine CGRP drugs assessed for Clinical effectiveness & Economic impacts by recent ICER report

    • April 14, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more